Direct Answer
Melanotan II is a synthetic melanocortin receptor agonist studied in animal models and a small number of early human reports. It is an unlicensed research chemical not approved for human use, and its unregulated use has been associated with adverse effects, including changes in pigmented skin lesions.
Summary Table
Evidence Level
Low
Key Information
Classification
Key Takeaways
- Melanotan II is an unlicensed melanocortin receptor agonist
- Most evidence is from animal studies; human data are limited
- Unregulated use has been associated with adverse effects, including changes in moles
Scientific Overview
In Plain English
Melanotan II is a lab-made peptide that acts on melanocortin receptors (involved in skin pigmentation and other functions). Most evidence is from animal studies. It is sold without approval as a tanning or sexual-function product, is not quality-controlled, and case reports link unregulated use to harms such as new or changing moles.
Scientific Details
Melanotan II is a cyclic melanocortin receptor agonist examined in animal models, for example peripheral nerve regeneration and thermogenesis. Review literature documents risks associated with unregulated use of alpha-melanocyte-stimulating hormone analogues, and case reports describe melanoma diagnosed in users. Human outcome and safety data are limited, and it is not an approved product.
How It Works
Melanotan II is a melanocortin receptor agonist. Pigmentation (skin tanning) is the melanocortin pathway's best-known effect and the basis for its unapproved cosmetic use; the cited animal studies examined other melanocortin-mediated effects such as peripheral nerve regeneration and thermogenesis.
Mechanism of Action
Melanocortin receptor agonism
animal
Animal studies of melanotan II describe melanocortin-receptor-mediated effects such as peripheral nerve regeneration and thermogenesis.
Evidence Level
Human Evidence
Human evidence is limited to small early reports and case reports; review literature highlights safety risks of unregulated use.
Animal Evidence
Animal studies examine melanocortin effects such as nerve regeneration and thermogenesis.
Limitations
Melanotan II is unlicensed and is often obtained without quality control; reported harms include changes in pigmented lesions. Robust human outcome data are lacking.
Why This Grade
Graded low: the cited evidence is mainly animal studies of melanocortin effects, plus a human melanoma case report and a review of the risks of unregulated α-MSH analogue use. Melanotan II is unlicensed and often obtained without quality control, robust human outcome data are lacking, and reported harms include changes in pigmented lesions — so the grade reflects limited human data dominated by safety concerns rather than demonstrated benefit.
Frequently Asked Questions
Is Melanotan II safe?
Melanotan II is an unlicensed research chemical that is not approved for human use, and its safety is not established. Because it is typically obtained without quality control, purity and dose are uncertain. Unregulated use has been associated with real harms: changes in pigmented skin lesions (moles), and a published case report describes melanoma associated with melanotan-II use. A dermatology review specifically highlights the safety risks of unregulated alpha-melanocyte-stimulating-hormone analogue use. Robust human outcome data are lacking, and most of what is known comes from animal studies and a small number of early human reports.
Is Melanotan II approved or legal to use?
No — it is an unlicensed research chemical, not approved for human use. Most of the evidence for it comes from animal studies, with only limited early human reports.
What's the difference between Melanotan II and PT-141 (bremelanotide)?
Both are melanocortin-receptor agonists, but they differ sharply in regulatory status and safety. Melanotan II is an unlicensed research chemical that is not approved for human use; most of its evidence is from animal studies, human data are limited, and unregulated use has been associated with changes in moles/pigmented skin lesions (including a case report of melanoma). PT-141 (bremelanotide) is a separate, FDA-approved melanocortin-agonist prescription medicine (Vyleesi), covered in its own entry. This is a comparison of what each one is and its approval status — not a claim that either is more effective than the other.
References
- The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat. European Journal of Pharmacology.Animal Studydoi:10.1016/s0014-2999(02)02945-x →
- Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice. Experimental Physiology.Animal Studydoi:10.1113/EP088838 →
- Melanoma associated with the use of melanotan-II. Dermatology.Human Studydoi:10.1159/000356389 →
- Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology.Reviewdoi:10.1111/ijd.13585 →
Alternative Names
- MT-II
- MT-2
- melanotan-II
Claim Boundaries
ION BLUE is an educational research aggregator. This content summarizes published scientific literature. It is not medically reviewed, is not medical advice, and is not a recommendation to use any substance. Several peptides discussed are research chemicals not approved for human use. Consult a licensed healthcare provider. Melanotan II is unlicensed and associated with documented harms; this entry is not a recommendation to obtain or use it.
This page summarizes published research and is for informational purposes only; it is not medical advice.